Skip to search formSkip to main contentSkip to account menu

yttrium Y 90 monoclonal antibody Lym-1

Known as: yttrium Y 90 MOAB Lym-1, monoclonal antibody Lym-1, yttrium Y 90, MOAB Lym-1, yttrium Y 90 
A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with yttrium 90 (Y-90). MoAb Lym-1 recognizes an epitope of the… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients…
Radioimmunotherapy using radiolabeled monoclonal antibodies against tumor-associated antigens has been efficacious, particularly… 
Highly Cited
1999
Highly Cited
1999
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
Antilymphoma mouse monoclonal antibody (MoAb) Lym-1, labeled with 67Cu or 131I, has demonstrated promising results in… 
Review
1999
Review
1999
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
UNLABELLED Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced therapeutic responses in… 
Highly Cited
1998
Highly Cited
1998
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
PURPOSE This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non… 
Highly Cited
1998
Highly Cited
1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
PURPOSE Lym-1, a monoclonal antibody (MoAb) that preferentially targets malignant lymphocytes, has induced therapeutic responses… 
Highly Cited
1997
Highly Cited
1997
Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia
Because most patients with advanced non‐Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to… 
1996
1996
Antibody responses to macrocycles in lymphoma.
UNLABELLED Metallic radioimmunoconjugates have promise for radioimmunoimaging and therapy. Macrocyclic chelating agents allow… 
Highly Cited
1996
Highly Cited
1996
A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake.
A murine antihuman B-cell monoclonal antibody, Lym-1, has shown considerable promise for the treatment of human malignant… 
Review
1994
Review
1994
Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131 i‐lym‐1 as a model
The radiation dose‐limiting toxicity from radioimmu‐notherapy has been myelotoxicity in the absence of bone marrow reconstitution… 
Highly Cited
1990
Highly Cited
1990
Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.
Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)